Shire gives attention to deficit of comparative data in ADHD and beyond
This article was originally published in Scrip
Executive Summary
In what is destined to become a mantra for specialty biopharmaceutical company Shire across a range of its products, the company plans to identify the value differential of its treatment for attention deficit hyperactivity disorder Vyvanse against a competitor, Johnson & Johnson's Concerta.